Welcome to the Green Rush, a KCSA Strategic Communications Production, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets and culture.

This week we wanted to revisit our conversation with special guest Dr. Hans Eriksson, Chief Medical Officer for HMNC Brain Health. Hans joined us to discuss his role at HMNC, the company’s research and development efforts to identify and bring to market treatments for mental health disorders, and the latest news and progress on the psychedelics movement.

With the death of the beloved actor Matthew Perry back in the news, we spoke with Hans about illicit ketamine use and how the news about Perry’s use was presented by the media, and the risks associated with the treatment.

If you are interested in learning more about Hans or to check out the latest updates from HMNC Brain Health, visit the links in our show notes. Also, be sure to follow HMNC and Hans on LinkedIn.

So, sit back and enjoy our conversation with Dr. Hans Eriksson of HMNC Brain Health.

Links, mentions, and socials:

HMNC Brain Health: hmnc-brainhealth.comHMNC Brain Health LinkedIn: de.linkedin.com/company/hmnc-brain-healthDr. Hans Eriksson LinkedIn: linkedin.com/in/hansaerikssonhttps://www.washingtonpost.com/entertainment/2024/05/22/matthew-perry-death-investigation-ketamine/ 

Show Credits:

This episode was hosted by Nick Opich and Anne Donohoe of KCSA Strategic Communications. 

Special thanks to our Program Director Shea Gunther.

You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing [email protected]. You can also connect with us via our social channels:

X: @KCSAPodcastLabs

Instagram: @KCSAPodcastLabs

LinkedIn: linkedin.com/company/thegreenrushpodcast